Santhoshkumar Sundaramoorthy1, Preethi Devanand1, Min Sook Ryu1, Kye Yong Song2, Dong Young Noh3, In Kyoung Lim4,5. 1. Division of Medical Sciences, BK21 Plus program, Graduate School of Ajou University, Suwon, 16499, Republic of Korea. 2. Department of Pathology, Chung-Ang University College of Medicine, Seoul, 156-756, Republic of Korea. 3. Department of Surgery, Seoul National University, Seoul, 03080, Republic of Korea. 4. Division of Medical Sciences, BK21 Plus program, Graduate School of Ajou University, Suwon, 16499, Republic of Korea. iklim@ajou.ac.kr. 5. Department of Biochemistry and Molecular Biology, Ajou University School of Medicine, Suwon, 16499, Republic of Korea. iklim@ajou.ac.kr.
Abstract
PURPOSE: It has been reported that PI3K/AKT pathway is altered in various cancers and AKT isoforms specifically regulate cell growth and metastasis of cancer cells; AKT1, but not AKT2, reduces invasion of cancer cells but maintains cancer growth. We propose here a novel mechanism of the tumor suppresser, TIS21/BTG2, that inhibits both growth and invasion of triple negative breast cancer cells via AKT1 activation by differential regulation of mTORc1 and mTORc2 activity. METHODS: Transduction of adenovirus carrying TIS21/BTG2 gene and transfection of short interfering RNAs were employed to regulate TIS21/BTG2 gene expression in various cell lines. Treatment of mTOR inhibitors and mTOR kinase assays can evaluate the role of mTORc in the regulation of AKT phosphorylation at S473 residue by TIS21/BTG2 in breast cancer cells. Open data and immunohistochemical analysis were performed to confirm the role of TIS21/BTG2 expression in various human breast cancer tissues. RESULTS: We observed that TIS21/BTG2 inhibited mTORc1 activity by reducing Raptor-mTOR interaction along with upregulation of tsc1 expression, which lead to significant reduction of p70S6K activation as opposed to AKT1S473, but not AKT2, phosphorylation via downregulating PHLPP2 (AKT1-specific phosphatase) in breast cancers. TIS21/BTG2-induced pAKTS473 required Rictor-bound mTOR kinase, indicating activation of mTORc2 by TIS21/BTG2 gene. Additionally, the TIS21/BTG2-induced pAKTS473 could reduce expression of NFAT1 (nuclear factor of activated T cells) and its target genes, which regulate cancer microenvironment. CONCLUSIONS: TIS21/BTG2 significantly lost in the infiltrating ductal carcinoma, but it can inhibit cancer growth via the TIS21/BTG2-tsc1/2-mTORc1-p70S6K axis and downregulate cancer progression via the TIS21/BTG2-mTORc2-AKT1-NFAT1-PHLPP2 pathway.
PURPOSE: It has been reported that PI3K/AKT pathway is altered in various cancers and AKT isoforms specifically regulate cell growth and metastasis of cancer cells; AKT1, but not AKT2, reduces invasion of cancer cells but maintains cancer growth. We propose here a novel mechanism of the tumor suppresser, TIS21/BTG2, that inhibits both growth and invasion of triple negative breast cancer cells via AKT1 activation by differential regulation of mTORc1 and mTORc2 activity. METHODS: Transduction of adenovirus carrying TIS21/BTG2 gene and transfection of short interfering RNAs were employed to regulate TIS21/BTG2 gene expression in various cell lines. Treatment of mTOR inhibitors and mTOR kinase assays can evaluate the role of mTORc in the regulation of AKT phosphorylation at S473 residue by TIS21/BTG2 in breast cancer cells. Open data and immunohistochemical analysis were performed to confirm the role of TIS21/BTG2 expression in various humanbreast cancer tissues. RESULTS: We observed that TIS21/BTG2 inhibited mTORc1 activity by reducing Raptor-mTOR interaction along with upregulation of tsc1 expression, which lead to significant reduction of p70S6K activation as opposed to AKT1S473, but not AKT2, phosphorylation via downregulating PHLPP2 (AKT1-specific phosphatase) in breast cancers. TIS21/BTG2-induced pAKTS473 required Rictor-bound mTOR kinase, indicating activation of mTORc2 by TIS21/BTG2 gene. Additionally, the TIS21/BTG2-induced pAKTS473 could reduce expression of NFAT1 (nuclear factor of activated T cells) and its target genes, which regulate cancer microenvironment. CONCLUSIONS:TIS21/BTG2 significantly lost in the infiltrating ductal carcinoma, but it can inhibit cancer growth via the TIS21/BTG2-tsc1/2-mTORc1-p70S6K axis and downregulate cancer progression via the TIS21/BTG2-mTORc2-AKT1-NFAT1-PHLPP2 pathway.
Authors: D Guardavaccaro; G Corrente; F Covone; L Micheli; I D'Agnano; G Starace; M Caruso; F Tirone Journal: Mol Cell Biol Date: 2000-03 Impact factor: 4.272
Authors: Yasuhiro Oki; Michelle Fanale; Jorge Romaguera; Luis Fayad; Nathan Fowler; Amanda Copeland; Felipe Samaniego; Larry W Kwak; Sattva Neelapu; Michael Wang; Lei Feng; Anas Younes Journal: Br J Haematol Date: 2015-07-27 Impact factor: 6.998
Authors: Tae Jun Park; Ji Yeon Kim; S Paul Oh; So Young Kang; Bong Wan Kim; Hee Jung Wang; Kye Yong Song; Hyoung Chin Kim; In Kyoung Lim Journal: Hepatology Date: 2008-05 Impact factor: 17.425
Authors: Milana A Bergamino; Gabriele Morani; Joel Parker; Eugene F Schuster; Mariana F Leal; Elena López-Knowles; Holly Tovey; Judith M Bliss; John F R Robertson; Ian E Smith; Mitch Dowsett; Maggie C U Cheang Journal: Clin Cancer Res Date: 2022-03-15 Impact factor: 13.801